{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:56:04Z","timestamp":1771512964100,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.amjopharm.2011.09.004","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T15:07:04Z","timestamp":1319555224000},"page":"471-482","source":"Crossref","is-referenced-by-count":5,"title":["Drug Utilization Patterns and Cardiovascular Outcomes in Elderly Patients Newly Initiated on Atorvastatin or Simvastatin"],"prefix":"10.1016","volume":"9","author":[{"given":"Jason P.","family":"Swindle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Potash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Kulakodlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Buikema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2011.09.004_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1076-7460.2002.00998.x","article-title":"Obesity, diabetes, and risk of cardiovascular disease in the elderly","volume":"11","author":"Wilson","year":"2002","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(97)04430-9","article-title":"Total cholesterol and risk of mortality in the oldest old","volume":"350","author":"Weverling-Rijnsburger","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib6","first-page":"9","article-title":"Epidemiology of cardiovascular disease in the elderly: an assessment of risk factors","volume":"22","author":"Kannel","year":"1992","journal-title":"Cardiovasc Clin"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(01)05553-2","article-title":"Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study","volume":"358","author":"Schatz","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3810\/pgm.2010.09.2211","article-title":"The prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic aged \u226565 years, by lipid lowering medication use status","volume":"122","author":"Candrilli","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2165\/00003495-199753050-00011","article-title":"Atorvastatin","volume":"53","author":"Lea","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1527-3466.2008.00047.x","article-title":"Simvastatin: two decades in a circle","volume":"26","author":"Kolovou","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clinthera.2007.02.001","article-title":"A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin","volume":"29","author":"Rogers","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib14","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-147-1-200707030-00002","article-title":"Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease","volume":"147","author":"Wenger","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib17","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"96","author":"Miettinen","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.amjopharm.2011.09.004_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"Sever","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/11318270-000000000-00000","article-title":"Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges","volume":"26","author":"Robinson","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib21","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2337\/dc06-0872","article-title":"Analysis of efficacy and safety in patients aged 65\u201375 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"29","author":"Neil","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib22","doi-asserted-by":"crossref","first-page":"M398","DOI":"10.1093\/gerona\/57.6.M398","article-title":"Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home","volume":"57","author":"Ghosh","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib23","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0735-1097(02)02477-4","article-title":"Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients","volume":"40","author":"Allen Maycock","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/heart.89.4.417","article-title":"Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?","volume":"89","author":"DeWilde","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2005.06.039","article-title":"Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: results from the ELIAGE and ELICOEUR surveys","volume":"111","author":"Cournot","year":"2006","journal-title":"Int J Cardiol"},{"issue":"Suppl 8A","key":"10.1016\/j.amjopharm.2011.09.004_bib26","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/107424840100600302","article-title":"Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions","volume":"6","author":"Davidson","year":"2001","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002512-200825080-00003","article-title":"Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?","volume":"25","author":"Maroo","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib29","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2007.01.067","article-title":"Safety of aggressive lipid management","volume":"49","author":"Davidson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/hrt.2006.110197","article-title":"Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice","volume":"93","author":"Choudhry","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib36","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/eurheartj\/ehl180","article-title":"Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS","volume":"27","author":"Ray","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib37","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4065\/83.12.1316","article-title":"Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.clinthera.2008.01.003","article-title":"Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States","volume":"30","author":"Foody","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib39","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1185\/03007990802405577","article-title":"Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience","volume":"24","author":"Willke","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1503\/cmaj.1041403","article-title":"Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect","volume":"172","author":"Zhou","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjopharm.2007.10.002","article-title":"Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice","volume":"5","author":"Harley","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.amjopharm.2011.09.004_bib42","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1185\/03007990802203279","article-title":"Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study","volume":"24","author":"Foody","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594611001474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T15:34:14Z","timestamp":1560872054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594611001474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1543594611001474"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2011.09.004","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}